Potential success could be head-scratcher for Novo Nordisk chair
If Novo Nordisk succeeds with its growth ambition, the company would face increasing complexity within its business, says Chair Helge Lund.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The organization would become more difficult to operate should Novo Nordisk reach its ambition of continuing on its current growth track, which has catapulted the company all the way to the upper echelons as one of the world’s biggest pharmaceutical companies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
